The following is a pass-along email from Just Labs magazine
Texas Veterinary Cancer Registry Expands Nationally
Coming in June, an interview with Dr. Theresa Fossum on her research and goals on the Just Labs website. If you have a question, send it to Jill LaCross, and she’ll pass it along.
WASHINGTON, D.C. – International speaker, author, Vice Chancellor for Global and Corporate Partnerships at The Texas A&M University System and founder of the Texas Veterinary Cancer Registry (http://texasvetcancerregistry.com), Dr. Theresa W. Fossum, today announced that the not-for-profit is launching the National Veterinary Cancer Registry (NVCR) for the purpose of reaching the hundreds of thousands of diagnosed pets and pet owners to advance medical treatment for naturally occurring diseases that affect animals and humans.
“Since the development of the Texas Veterinary Cancer Registry, we have received overwhelming support from pet owners, researchers, oncologists and stakeholders for our work,” Dr. Fossum said. “As a result, we have accepted the call to expand our efforts nationally. We could not have chosen a more appropriate time to launch the national registry since our first priority is to care for the loving animals that have been diagnosed with cancer, and May is National Pet Month.”
The National Veterinary Cancer Registry (https://nationalveterinarycancerregistry.org) is a national database formed to identify and register pets diagnosed with cancer in order to facilitate and promote medical treatments that lead to advances, higher success rates and cures for cancer in pets and people.
“The registry is a product of a lifetime of work in medical science,” Dr. Fossum said. “There are already successful cases throughout Texas from the registry where, even without a cure for cancer, we have been able to drastically improve the quality of life for pets diagnosed with cancer, while also advancing medical treatments. I am thrilled to see this registry expand to a national level, because as we broaden our reach, more pets can be treated and the science behind those treatments can advance.”
More about the National Veterinary Cancer Registry (NVCR)
The National Veterinary Cancer Registry (NVCR) is an animal care database formed to identify and register pets with cancer to facilitate and promote medical treatments that will lead to cures for cancer in pets and people. A joint effort of the CARE Foundation, Baylor University Medical Center (BUMC)at Dallas and the Texas Veterinary Oncology Group, NVCR will advance medical breakthroughs in both animal and human care, helping to ensure that new treatments available for cancer in humans become available to animals in an efficient and timely manner. The NVCR will advance veterinary cancer research by gathering information from pet owners whose pets have been diagnosed with a naturally occurring cancer. Subsequent enrollment in clinical trials of new drugs and devices to improve the animal’s healthcare may be possible.
About Dr. Theresa W. Fossum
Vice Chancellor for Global and Corporate Partnerships,The Texas A&M University System, and founder of NVCR, Theresa W. Fossum, DVM, M.S., Ph.D., Diplomate American College of Veterinary Surgeons (ACVS), is a professor of surgery and holder of the Tom and Jean Read Chair in Veterinary Surgery at Texas A&M University. Fossum also serves as both director of the Texas A&M Institute for Preclinical Studies (TIPS), and director for Cardiothoracic Surgery and Biomedical Devices at Texas A&M’s Michael E. DeBakey Institute. Fossum is a world-renowned surgeon and author of Small Animal Surgery, the most widely used academic text on the subject. Her main interests include diseases of the respiratory and cardiovascular system, including cardiopulmonary bypass procedures, and she is a frequently cited expert on chylothorax and other respiratory and surgical diseases. She is the principle investigator of numerous research projects, and as director of TIPS, oversees the leading national program to utilize comprehensive preclinical studies under Good Laboratory Practices (GLP) and biomedical imaging to markedly enhance the quality and speed of drug and medical device development.